NASDAQ:ENOB

Enochian Biosciences Competitors

$3.54

-0.25 (-6.60 %)

(As of 02/26/2021 12:00 AM ET)

Add

Compare

Today's Range

$3.39

Now: $3.54▼

$3.78

50-Day Range

$3.02

MA: $3.63▼

$4.51

52-Week Range

$1.95

Now: $3.54▼

$13.43

Volume112,855 shs

Average Volume167,867 shs

Market Capitalization$169.08 million

P/E RatioN/A

Dividend YieldN/A

Beta0.5

Enochian Biosciences (NASDAQ:ENOB) Vs. CALT, ALBO, XENE, BCEL, CMRX, and KALV

Should you be buying ENOB stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Enochian Biosciences, including Calliditas Therapeutics AB (publ) (CALT), Albireo Pharma (ALBO), Xenon Pharmaceuticals (XENE), Atreca (BCEL), Chimerix (CMRX), and KalVista Pharmaceuticals (KALV).

Enochian Biosciences vs. Calliditas Therapeutics AB (publ) Stock

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Enochian Biosciences (NASDAQ:ENOB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, institutional ownership and profitability.

Earnings and Valuation

This table compares Calliditas Therapeutics AB (publ) and Enochian Biosciences' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$19.56 million	34.40	$-3,450,000.00	($0.19)	-147.74
Enochian Biosciences	N/A	N/A	$-11,420,000.00	N/A	N/A

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Enochian Biosciences.

Institutional & Insider Ownership

11.9% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. Comparatively, 5.1% of Enochian Biosciences shares are held by institutional investors. 69.6% of Enochian Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Calliditas Therapeutics AB (publ) and Enochian Biosciences' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	N/A	-26.80%	-25.38%
Enochian Biosciences	N/A	-5.79%	-5.47%

Analyst Ratings

This is a breakdown of recent ratings for Calliditas Therapeutics AB (publ) and Enochian Biosciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0	0	5	0	3.00
Enochian Biosciences	0	0	0	0	N/A

Calliditas Therapeutics AB (publ) currently has a consensus target price of $40.80, indicating a potential upside of 45.35%. Given Calliditas Therapeutics AB (publ)'s higher probable upside, analysts plainly believe Calliditas Therapeutics AB (publ) is more favorable than Enochian Biosciences.

Summary

Calliditas Therapeutics AB (publ) beats Enochian Biosciences on 5 of the 8 factors compared between the two stocks.

Enochian Biosciences vs. Albireo Pharma Stock

Albireo Pharma (NASDAQ:ALBO) and Enochian Biosciences (NASDAQ:ENOB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, institutional ownership and profitability.

Profitability

This table compares Albireo Pharma and Enochian Biosciences' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Albireo Pharma	-751.53%	-71.22%	-42.91%
Enochian Biosciences	N/A	-5.79%	-5.47%

Analyst Ratings

This is a breakdown of recent ratings for Albireo Pharma and Enochian Biosciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Albireo Pharma	0	0	8	0	3.00
Enochian Biosciences	0	0	0	0	N/A

Albireo Pharma currently has a consensus target price of $69.4286, indicating a potential upside of 99.16%. Given Albireo Pharma's higher probable upside, analysts plainly believe Albireo Pharma is more favorable than Enochian Biosciences.

Institutional & Insider Ownership

85.7% of Albireo Pharma shares are held by institutional investors. Comparatively, 5.1% of Enochian Biosciences shares are held by institutional investors. 5.0% of Albireo Pharma shares are held by insiders. Comparatively, 69.6% of Enochian Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Albireo Pharma and Enochian Biosciences' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Albireo Pharma	$9.64 million	68.99	$-62,720,000.00	($5.04)	-6.92
Enochian Biosciences	N/A	N/A	$-11,420,000.00	N/A	N/A

Enochian Biosciences has lower revenue, but higher earnings than Albireo Pharma.

Volatility and Risk

Albireo Pharma has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500. Comparatively, Enochian Biosciences has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500.

Enochian Biosciences vs. Xenon Pharmaceuticals Stock

Enochian Biosciences (NASDAQ:ENOB) and Xenon Pharmaceuticals (NASDAQ:XENE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Profitability

This table compares Enochian Biosciences and Xenon Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Enochian Biosciences	N/A	-5.79%	-5.47%
Xenon Pharmaceuticals	-102.25%	-21.76%	-16.08%

Analyst Ratings

This is a summary of current ratings and target prices for Enochian Biosciences and Xenon Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enochian Biosciences	0	0	0	0	N/A
Xenon Pharmaceuticals	0	0	6	0	3.00

Xenon Pharmaceuticals has a consensus price target of $23.00, indicating a potential upside of 23.13%. Given Xenon Pharmaceuticals' higher probable upside, analysts plainly believe Xenon Pharmaceuticals is more favorable than Enochian Biosciences.

Insider and Institutional Ownership

5.1% of Enochian Biosciences shares are held by institutional investors. Comparatively, 79.9% of Xenon Pharmaceuticals shares are held by institutional investors. 69.6% of Enochian Biosciences shares are held by company insiders. Comparatively, 8.4% of Xenon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Enochian Biosciences and Xenon Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enochian Biosciences	N/A	N/A	$-11,420,000.00	N/A	N/A
Xenon Pharmaceuticals	$6.83 million	95.74	$-41,600,000.00	($1.54)	-12.13

Enochian Biosciences has higher earnings, but lower revenue than Xenon Pharmaceuticals.

Volatility & Risk

Enochian Biosciences has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500. Comparatively, Xenon Pharmaceuticals has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500.

Enochian Biosciences vs. Atreca Stock

Enochian Biosciences (NASDAQ:ENOB) and Atreca (NASDAQ:BCEL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Profitability

This table compares Enochian Biosciences and Atreca's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Enochian Biosciences	N/A	-5.79%	-5.47%
Atreca	N/A	-43.21%	-40.98%

Analyst Ratings

This is a summary of current ratings and target prices for Enochian Biosciences and Atreca, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enochian Biosciences	0	0	0	0	N/A
Atreca	0	0	6	0	3.00

Atreca has a consensus price target of $29.00, indicating a potential upside of 67.15%. Given Atreca's higher probable upside, analysts plainly believe Atreca is more favorable than Enochian Biosciences.

Insider and Institutional Ownership

5.1% of Enochian Biosciences shares are held by institutional investors. Comparatively, 69.6% of Atreca shares are held by institutional investors. 69.6% of Enochian Biosciences shares are held by company insiders. Comparatively, 9.9% of Atreca shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Enochian Biosciences and Atreca's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enochian Biosciences	N/A	N/A	$-11,420,000.00	N/A	N/A
Atreca	N/A	N/A	$-67,480,000.00	($4.26)	-4.07

Volatility & Risk

Enochian Biosciences has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500. Comparatively, Atreca has a beta of 0.08, indicating that its stock price is 92% less volatile than the S&P 500.

Summary

Enochian Biosciences beats Atreca on 5 of the 8 factors compared between the two stocks.

Enochian Biosciences vs. Chimerix Stock

Enochian Biosciences (NASDAQ:ENOB) and Chimerix (NASDAQ:CMRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Profitability

This table compares Enochian Biosciences and Chimerix's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Enochian Biosciences	N/A	-5.79%	-5.47%
Chimerix	-321.31%	-36.57%	-33.53%

Analyst Ratings

This is a summary of current ratings and target prices for Enochian Biosciences and Chimerix, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enochian Biosciences	0	0	0	0	N/A
Chimerix	0	0	2	0	3.00

Chimerix has a consensus price target of $13.00, indicating a potential upside of 32.52%. Given Chimerix's higher probable upside, analysts plainly believe Chimerix is more favorable than Enochian Biosciences.

Insider and Institutional Ownership

5.1% of Enochian Biosciences shares are held by institutional investors. Comparatively, 45.4% of Chimerix shares are held by institutional investors. 69.6% of Enochian Biosciences shares are held by company insiders. Comparatively, 9.0% of Chimerix shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Enochian Biosciences and Chimerix's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enochian Biosciences	N/A	N/A	$-11,420,000.00	N/A	N/A
Chimerix	$12.52 million	49.08	$-112,580,000.00	($0.86)	-11.41

Enochian Biosciences has higher earnings, but lower revenue than Chimerix.

Volatility & Risk

Enochian Biosciences has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500. Comparatively, Chimerix has a beta of 1.88, indicating that its stock price is 88% more volatile than the S&P 500.

Enochian Biosciences vs. KalVista Pharmaceuticals Stock

Enochian Biosciences (NASDAQ:ENOB) and KalVista Pharmaceuticals (NASDAQ:KALV) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Volatility & Risk

Enochian Biosciences has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500. Comparatively, KalVista Pharmaceuticals has a beta of 2.13, indicating that its stock price is 113% more volatile than the S&P 500.

Profitability

This table compares Enochian Biosciences and KalVista Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Enochian Biosciences	N/A	-5.79%	-5.47%
KalVista Pharmaceuticals	-229.45%	-47.45%	-41.84%

Earnings & Valuation

This table compares Enochian Biosciences and KalVista Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enochian Biosciences	N/A	N/A	$-11,420,000.00	N/A	N/A
KalVista Pharmaceuticals	$12.69 million	46.47	$-29,120,000.00	($1.64)	-20.04

Enochian Biosciences has higher earnings, but lower revenue than KalVista Pharmaceuticals.

Analyst Ratings

This is a summary of current ratings and target prices for Enochian Biosciences and KalVista Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enochian Biosciences	0	0	0	0	N/A
KalVista Pharmaceuticals	0	0	6	0	3.00

KalVista Pharmaceuticals has a consensus price target of $50.1667, indicating a potential upside of 52.62%. Given KalVista Pharmaceuticals' higher probable upside, analysts plainly believe KalVista Pharmaceuticals is more favorable than Enochian Biosciences.

Insider and Institutional Ownership

5.1% of Enochian Biosciences shares are held by institutional investors. Comparatively, 90.2% of KalVista Pharmaceuticals shares are held by institutional investors. 69.6% of Enochian Biosciences shares are held by company insiders. Comparatively, 18.0% of KalVista Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.